
Stem cell therapy gets positive CHMP opinion for blood cancers
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting conditional marketing authorisation for Zemcelpro (UM171 cell therapy). The positive opinion relates to the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following… Read More













